Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial

Autor: Julian Gunn, Iain B. Squire, David Adlam, Renaud Fay, Yasir Parviz, Faiez Zannad, Bertram Pitt, Javaid Iqbal

Publikováno v: European Journal of Heart Failure
European Journal of Heart Failure, Oxford University Press (OUP), 2014, 16 (6), pp.685-691. ⟨10.1002/ejhf.88⟩

Aims EPHESUS was a multicentre, double-blind clinical trial in which 6632 patients with acute myocardial infarction (AMI) complicated by LV systolic dysfunction (LVSD) were randomized to receive eplerenone (n = 3319) or placebo (n = 3313). A total of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44d7524729a58c2f054e0af4cb0339e2
https://doi.org/10.1002/ejhf.88

Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and HypertensionNovelty and Significance

Autor: Martinez-Martinez, Ernesto, Calvier, Laurent, Fernández-Celis, Amaya, Rousseau, Elodie, Jurado-López, Raquel, Rossoni, Luciana, Jaisser, Frederic, Zannad, Faiez, Rossignol, Patrick, Cachofeiro, Victoria, López-Andrés, Natalia

Publikováno v: Hypertension
Hypertension, American Heart Association, 2015, 66 (4), pp.767-775. ⟨10.1161/HYPERTENSIONAHA.115.05876⟩
Hypertension, 2015, 66 (4), pp.767-775. ⟨10.1161/HYPERTENSIONAHA.115.05876⟩

International audience; Hypertensive cardiac remodeling is accompanied by molecular inflammation and fibrosis, 2 mechanisms that finally affect cardiac function. At cardiac level, aldosterone promotes inflammation and fibrosis, although the precise m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::082208f0adbe6b3cc4015c43dcfb33b9
https://hal.univ-lorraine.fr/hal-01745541

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease

Autor: So Young Kim, Piotr Ponikowski, Stefan D. Anker, Henry Krum, Michael Böhm, Lars Køber, Christina Nowack, Mihai Gheorghiade, Bertram Pitt, Gerasimos Filippatos, Adriaan A. Voors, Aldo P. Maggioni, Faiez Zannad, Nina Kimmeskamp-Kirschbaum, Alexander Pieper

Publikováno v: European Journal of Heart Failure
European Journal of Heart Failure, Oxford University Press (OUP), 2015, 17 (2), pp.224-232. ⟨10.1002/ejhf.218⟩
European Journal of Heart Failure, 17(2), 224-232. Wiley

International audience; AIMS:To investigate the safety and potential efficacy of the novel non-steroidal mineralocorticoid receptor antagonist finerenone in patients with worsening chronic heart failure and reduced left ventricular ejection fraction

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d4975e18e99fc401a424c419b4911e4
https://hal.univ-lorraine.fr/hal-01758523

The Impact of Galectin-3 Inhibition on Aldosterone-Induced Cardiac and Renal Injuries

Autor: Laurent Calvier, Natalia López-Andrés, J. Rafael Sadaba, Elodie Rousseau, María Miana, Patrick Rossignol, Faiez Zannad, Ernesto Martínez-Martínez, Victoria Cachofeiro

Publikováno v: JACC: Heart Failure
JACC: Heart Failure, Elsevier/American College of Cardiology, 2015, 3 (1), pp.59-67. ⟨10.1016/j.jchf.2014.08.002⟩

Objectives This study investigated whether galectin (Gal)-3 inhibition could block aldosterone-induced cardiac and renal fibrosis and improve cardiorenal dysfunction. Background Aldosterone is involved in cardiac and renal fibrosis that is associated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9786126a820149c789e5237355956913
https://hal.univ-lorraine.fr/hal-01758739

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study

Autor: Rolf Wachter, Gerald Tremblay, Harry Shi, Anoop Chauhan, Antonio Fernández Ortiz, Miguel Fiol Sala, Jerzy Lewczuk, Andrew Grieve, Rainer Hambrecht, Pierre Coste, Jean-Philippe Collet, J. M. Ten Berg, Jan Vojacek, J. Herrman, Witold Zmuda, Juan Ramon Rey Blas, Emmanuel Teiger, Jaroslav Sumbal, David Smith, Faiez Zannad, Geza Lupkovics, Karol Micko, Johann Bauersachs, Minakshi Madan, Cosme Garcia Garcia, Jerzy Gorny, Marcus Flather, Robert C. Welsh, Carlos Perez Muñoz, David Fitchett, Ruth H. Strasser, Karsten Sydow, Robin A.P. Weir, Miguel Orri, Michel Barboteu, Thomas Münzel, Gilles Montalescot, Georg Noll, Harald Mudra, János Tomcsányi, Serge Lepage, W. Stuart Hillis, Jiri Kettner, Roman Margoczy, Csaba András Dézsi, Thomas N. Martin, Jacek Kubica, Gilles Zemour, Franciso Ridocci Soriano, Dawn L. Adamson, Stephan Steiner, Marian Hranai, Filippatos Gerasimos, Farqad Alamgir, Jean-Lucien Rouleau, Bruce Sussex, Martin Hutyra, Gregory Y.H. Lip, Dimitros Alexopoulos, Michael Böhm, Graham C. Wong, Dominique Ducos, Michel Galinier, Bertram Pitt, Eva Turgonyi, Petr Ostadal, Christian W. Hamm, Freek W.A. Verheugt, Carsten Tschöpe, Esteban López de Sá, Vlassios N Pyrgakis, Jindrich Spinar, Blair J. O'Neill, Hubertus Heuer, Gerhard Hauf, John Vincent, Nikos Werner, David E. Newby, Frantisek Kovar, Dimitrios Babalis, Yves Cottin, Peter Polgar, Gerry P McCann, Xavier Bosch Genover

Publikováno v: European Heart Journal
European Heart Journal, 2014, 35 (34), pp.2295-2302. ⟨10.1093/eurheartj/ehu164⟩
European Heart Journal, Oxford University Press (OUP): Policy B, 2014, 35 (34), pp.2295-2302. ⟨10.1093/eurheartj/ehu164⟩

International audience; AIMS:We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset.METHODS AND RESULTS:In this randomized, placebo-controlled, dou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb2312c3e0059a046fe64b78f40bc78
https://hal.univ-lorraine.fr/hal-01738642